GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (NAS:PHVS) » Definitions » Institutional Ownership

Pharvaris NV (Pharvaris NV) Institutional Ownership : 10.10% (As of Jun. 09, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pharvaris NV Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Pharvaris NV's institutional ownership is 10.10%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Pharvaris NV's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Pharvaris NV's Float Percentage Of Total Shares Outstanding is 76.47%.


Pharvaris NV Institutional Ownership Historical Data

The historical data trend for Pharvaris NV's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharvaris NV Institutional Ownership Chart

Pharvaris NV Historical Data

The historical data trend for Pharvaris NV can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 7.90 7.87 7.85 7.06 10.08 10.13 9.84 9.86 10.10 10.10

Pharvaris NV Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Pharvaris NV (Pharvaris NV) Business Description

Traded in Other Exchanges
Address
Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases.

Pharvaris NV (Pharvaris NV) Headlines